<DOC>
	<DOCNO>NCT01559038</DOCNO>
	<brief_summary>The current study ass real - life effectiveness adalimumab management articular dermatological manifestation moderate severe Psoriatic Arthritis ( PsA ) .</brief_summary>
	<brief_title>Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult &gt; = 18 year old Has provide write informed consent allow use data study provide permission contact study personnel Active Psoriatic Arthritis ( PsA ) three ( 3 ) tender swollen joint well active psoriatic skin lesion confirm history psoriasis Inadequate response nontolerant current diseasemodifying antirheumatic drug ( DMARD ) base treatment PsA Currently participate another prospective study include control clinical trial observational study Patient sign inform consent Stable disease adequate tolerance response current treatment change treatment indicate Previous treatment antitumor necrosis factor ( antiTNF ) biologic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Assessing Effectiveness Psoriatic Arthritis</keyword>
</DOC>